Advanced search
Publication Cover
Biomarkers Volume 13, 2008 - Issue 6
Submit an article Journal homepage
430
Views
40
CrossRef citations to date
0
Altmetric
Research Article

The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone

Emma L. Akuffo GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, UK,
,
John B. Davis GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, UK,
,
Steven M. Fox GlaxoSmithKline, Medicines Research Centre, Gunnels Wood RoadStevenage, SG1 2NY, UK,
,
Israel S. Gloger GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, UK,
,
David Hosford Targacep Inc., 200 East First Street Winston-Salem, NC, 27101-4165, USA,
,
Emma E. Kinsey GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, UK,
,
Neil A. Jones GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, UK,
,
Christina M. Nock PPD, Granta Park Cambridge, CB1 6GQ, UK,
,
Allen D. Roses Duke Drug Discovery Institute, Duke University Medical Center, Durham North Carolina, , 27710, USA,
,
Ann M. Saunders GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, North Carolina, 27709, USA,
,
J. Mark Skehel Cancer Research UK, London Research Institute, Clare Hall Laboratories, Blanche LaneSouth Mimms, Herts EN6 3LD, UK,
,
Marjorie A. Smith GlaxoSmithKline, Medicines Research Centre, Gunnels Wood RoadStevenage, SG1 2NY, UK,
&
Paul Cutler GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, CM19 5AW, UK, Correspondence[email protected]
 show all
Pages 618-636 | Accepted 02 Sep 2008, Published online: 07 Nov 2008

References

  • B Bjellqvist, C Pasquali, F Ravier, J-C Sanchez, and D. Hochstrasser. (1993). A nonlinear wide-range immobilized pH gradient for two-dimensional electrophoresis and its definition in a relevant pH scale. Electrophoresis 14:1357–1365.
  • M Bonifati, and U. Kishore. (2007). Role of complement in neurodegeneration and neuroinflammation. Molecular Immunology 44:999–1010.
  • P Cutler, EL Akuffo, WM Bodnar, DM Briggs, JB Davis, CM Debouck, SM Fox, RA Gibson, DA Gormley, JD Holbrook, AJ Hunter, EE Kinsey, R Prinjha, JC Richardson, AD Roses, MA Smith, N Tsokanas, DA Willé, W Wu, JW Yates, and IS. Gloger. (2008). Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clinical Applications 2:467–477.
  • AE Davis, C Shenge, and L. Dongxu. (2007). C1 inhibitor: Biologic activities that are independent of protease inhibition. Immunobiology 212:313–323.
  • S Honda, F Itoh, M Yoshimoto, S Ohno, Y Hinoda, and I. Kohzoh. (2000). Association between complement regulatory protein factor H and AM34 antigen, detected in senile plaques. Journal of Gerontology 55A:M265–M269.
  • A Hye, S Lynham, M Thambisetty, M Causevic, J Campbell, HL Byers, C Hooper, F Rijsdijk, SJ Tabrizi, S Banner, CE Shaw, C Foy, M Poppe, N Archer, G Hamilton, J Powell, RG Brown, P Sham, M Ward, and S. Lovestone. (2006). Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129:3042–3050.
  • D. Kovacs. (2000). Alpha-2-macroglobulin in late onset Alzheimer's disease. Experimental Gerontology 35:473–479.
  • S. Lovestone. (2006). Biomarkers in Alzheimer's disease. Journal of Nutrition, Health & Aging 10:118–122.
  • P McGeer, and E. McGeer. (2001). Polymorphisms in inflammatory genes and the risk of Alzheimer's disease. Archives of Neurology 58:1790–1792.
  • AE Pinnell, and BE. Northam. (1978). New automated dye-binding method for serum albumin determination with bromcresol purple. Clinical Chemistry 24:80–86.
  • ME Risner, AM Saunders, JFB Altman, GC Ormandy, S Craft, IM Foley, ME Zvartau-Hind, DA Hosford, and AD. Roses. (2006). Efficacy of rosiglitazone in a genetically defined population with mild to moderate Alzheimer's disease. The Pharmacogenomics Journal 6:246–254.
  • AD. Roses. (1996). Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annual Review Medicine 47:387–400.
  • PF Stahel, SmithWR, J Bruchis, CH. Rabb. (2008). Peroxisome Proliferator-Activated Receptors: ‘Key’ Regulators of Neuroinflammation after Traumatic Brain Injury. PPAR Research. 2008: 538141.
  • B Stevens, NJ Allen, LE Vazquez, GR Howell, KS Christopherson, N Nouri, KD Micheva, AK Mehalow, AD Huberman, B Stafford, A Sher, AM Litke, JD Lambris, SJ Smith, SWM John, and BA. Barres. (2007). The classical complement cascade mediates CNS synapse elimination. Cell 131:1164–1178.
  • R Strohmeyer, M Ramirez, G Coel, K Mueller, and J. Rogers. (2002). Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. Journal of Neuroimmunology 131:135–146.
  • Tooyama I. Interaction of alpha-2-macroglobulin and amyloid β peptide. (2001). Neuroinflammatory Mechanisms in Alzheimer's Disease 145–154.
  • ERLC Vardy, I Hussain, and NM. Hooper. (2006). Emerging therapeutics for Alzheimer's disease. Expert Review of Neurotherapeutics 6:695–704.
  • R Veerhuis, I Janssen, CE Hack, and P. Eikelenboom. (1996). Early complement components in Alzheimer's disease brain. Acta Neuropathology 91:53–60.
  • R Veerhuis, I Janssen, JJM Hoozemans, CJA De Groot, CE Hack, and P. Eikelenboom. (1998). Complement C1-Inhibitor expression in Alzheimer's disease. Acta Neuropathology 96:287–296.
  • R Verrhuis, I Janssen, JA De Groot, FL van Muiswinkel, CE Hack, and P. Eikelenboom. (1999). Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins but not C1-inhibitor. Experimental Neurology 160:289–299.
  • DG Walker, O Yasuhara, PA Patston, EG McGeer, and PL. McGeer. (1995). Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer's disease. Brain Research 675:75–82.
  • IR White, WJ Man, D Bryant, P Bugelski, P Camilleri, P Cutler, W Hayes, JD Holbrook, K Kramer, PG Lord, and J. Wood. (2003). Protein expression changes in Sprague Dawley rat liver proteome following administration of peroxisome proliferators activated receptor alpha and gamma ligands. Proteomics 3:505–512.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.